Latest News
Citius Oncology reports growing LYMPHIR adoption and market access
5 August 2026 - Biopharmaceutical company Citius Oncology Inc (Nasdaq: CTOR), a subsidiary of Citius Pharmaceuticals Inc (Nasdaq: CTXR), on Wednesday reported continued commercial progress for LYMPHIR, with the number of new institutional accounts or...
Obsidian Therapeutics advances Agni-01 study with first patient enrolled in registration-enabling cohort
5 August 2026 - Clinical-stage biopharmaceutical company Obsidian Therapeutics Inc (Nasdaq:OBX) on Wednesday announced enrolment of the first patient in the registration-enabling cohort of its Phase 1/2 Agni-01 study evaluating amsokigene autoleucel ...
CVS Health expands GLP-1 weight management access through integrated care offering
5 August 2026 - Health solutions company CVS Health (NYSE: CVS) announced on Wednesday that it has enhanced its weight management programme to improve access, affordability and support for eligible patients using GLP-1 medications. The expanded offer...
Summit Therapeutics expands ivonescimab programme into bladder cancer with Phase II/III trial
5 August 2026 - Biopharmaceutical oncology company Summit Therapeutics Inc (NASDAQ: SMMT) reported on Wednesday that it has expanded the global clinical development programme for its investigational bispecific antibody ivonescimab by launching the Ph...
Adyen to provide LillyDirect with payment technology services
5 August 2026 - Financial technology platform Adyen announced on Tuesday that it will help facilitate payment services for prescribed patients accessing Eli Lilly and Company's (NYSE:LLY) FDA-approved medicines and free home delivery through Lil...